NR1H4 and primary biliary cholangitis: In contrast, the discovery of highly selective FXR agonists could represent a new frontier in the treatment of primary biliary cirrhosis (PBC) and related cholestatic disorders where the concomitant activation of GPBAR1 could increase patient risk for adverse side effects.